North American Society For Pediatric Gastroenterology, Hepatology & Nutrition

North American Society For Pediatric Gastroenterology, Hepatology & Nutrition

Source:

Buti M, et al. Poster 680. Presented at: The Liver Meeting Digital Experience; Nov. 12-15, 2021 (virtual meeting).

Disclosures: Buti reports financial relationships with AbbVie, Gilead and Janssen.
December 21, 2021
1 min watch
Save

VIDEO: Bulevirtide improves quality of life in chronic HDV

Source:

Buti M, et al. Poster 680. Presented at: The Liver Meeting Digital Experience; Nov. 12-15, 2021 (virtual meeting).

Disclosures: Buti reports financial relationships with AbbVie, Gilead and Janssen.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Bulevirtide improved quality of life measures among patients treated for chronic hepatitis D virus, Maria Buti, MD, PhD, of the Hospital Universiario Valle Hebron, told Healio Gastroenterology.

In a multicenter, randomized, phase 3 study, researchers evaluated the health-related quality of life benefits as measured by the Hepatitis Quality of Life Questionnaire (HQLQ) following 24 weeks of either bulevirtide 2 mg (n = 49 patients with HDV) treatment or delayed treatment (n = 51 patients with HDV). From baseline to study conclusion, results yielded numeric improvements in all domains of the HQLQ among patients treated with bulevirtide. Measured outcomes included a greater than 5-point improvement in general health, bodily pain, vitality, mental health, hepatitis-specific limitations and hepatitis-specific health distress as well as a greater than 4-point improvement in social functioning and role-emotional domains. Among patients who underwent delayed treatment, Buti noted a greater than 5-point improvement in mental health and hepatitis-specific health distress as well as a greater than 4-point improvement in health-specific limitations.

Future research aims to investigate the burden of illness, course of disease and long-term effects of bulevirtide 2 mg treatment on patients with chronic HDV quality of life.